Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia

The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-oc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pautas, Cécile, Raffoux, Emmanuel, Lambert, Juliette, Legrand, Ollivier, Chantepie, Sylvain, Gastaud, Lauris, Marolleau, Jean-Pierre, Thomas, Xavier, Turlure, Pascal, Benner, Rebecca J., Vandendries, Erik, Gogat, Karïn, Dombret, Hervé, Castaigne, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189917/
https://www.ncbi.nlm.nih.gov/pubmed/33564120
http://dx.doi.org/10.1038/s41409-020-01207-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189917/
https://www.ncbi.nlm.nih.gov/pubmed/33564120
http://dx.doi.org/10.1038/s41409-020-01207-4

Ejemplares similares